The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and Epoetin
Open accessAbstract
BackgroundIn patients with end-stage renal dis- ease, anemia develops as a result of erythropoietin deficiency, and recombinant human erythropoietin (epoetin) is prescribed to correct the anemia partially.We examined the risks and benefits of normalizing the hematocrit in patients with cardiac disease who were undergoing hemodialysis. MethodsWe studied 1233 patients with clinical ev- idence of congestive heart failure or ischemic heart disease who were undergoing hemodialysis: 618 patients were assigned to receive increasing doses of epoetin to achieve and maintain a hematocrit of 42 percent, and 615 were assigned to receive doses of epoetin sufficient to maintain a hematocrit of 30 percent throughout the study.The median duration of treatment was 14 months.The primary end point was the length of time to death or a first nonfatal myocardial infarction. ResultsAfter 29 months, there were 183 deaths and 19 first nonfatal myocardial infarctions among the patients in the normal-hematocrit group and 150 deaths and 14 nonfatal myocardial infarctions among those in the low-hematocrit group (risk ratio for the normal-hematocrit group as compared with the lowhematocrit group, 1.3; 95 percent confidence interval, 0.9 to 1.9).Although the difference in event-free survival between the two groups did not reach the prespecified statistical stopping boundary, the study was halted.The causes of death in the two groups were similar.The mortality rates decreased with increasing hematocrit values in both groups.The patients in the normal-hematocrit group had a decline in the adequacy of dialysis and received intravenous iron dextran more often than those in the low-hematocrit group. ConclusionsIn patients with clinically evident congestive heart failure or ischemic heart disease who are receiving hemodialysis, administration of epoetin to raise their hematocrit to 42 percent is not recommended.(N
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The acute hemodynamic responses of EPO administration may result in impaired perfusion/oxygen supply to the tissues and contribute to acute adverse events such as enhanced PLT aggregation, thromboembolism, and myocardial ischemia (17, 45).”
From Red Blood Cell Function and Dysfunction: Redox Regulation, Nitric Oxide Metabolism, Anemia (2017) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
MCHORNEY, C. A., JOHNE, W., & ANASTASIAE, R. (1993) · Medical Care · doi:10.1097/00005650-199303000-00006 · Cited by 6,681
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Salonen, J. T., Nyyssönen, K., Korpela, H., Tuomilehto, J., Seppänen, R., & Salonen, R. (1992) · Circulation · doi:10.1161/01.cir.86.3.803 · Cited by 1,284
IRON AND THE SEX DIFFERENCE IN HEART DISEASE RISK
Sullivan, J. (1981) · The Lancet · doi:10.1016/s0140-6736(81)92463-6 · Cited by 969
Eschbach, J. W., Abdulhadi, M. H., Browne, J. K., Delano, B. G., Downing, M. R., Egrie, J. C., Evans, R. W., Friedman, E. A., Graber, S. E., Haley, N. R., et al. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-12-992 · Cited by 795
Self-citationImpact of left ventricular hypertrophy on survival in end-stage renal disease
Silberberg, J. S., Barré, P. E., Prichard, S. S., & Sniderman, A. D. (1989) · Kidney International · doi:10.1038/ki.1989.192 · Cited by 780
The Quality of Life of Hemodialysis Recipients Treated With Recombinant Human Erythropoietin
Evans, R. W. (1990) · JAMA · doi:10.1001/jama.263.6.825 · Cited by 401
Research works printed but not linked: 8
- Pascual J, 1991, Clin Nephrol, 35, 280
- Eschbach JW, 1993, J Am Soc Nephrol, 4, 425
- Collins A, 1994, J Am Soc Nephrol, 5, 439
- Nissenson AR, 1996, J Am Soc Nephrol, 7, 1459
- Barany P, 1996, J Am Soc Nephrol, 7, 1472
- Benz RL, 1996, J Am Soc Nephrol, 7, 1473
- Hoen B, 1995, Nephrol Dial Transplant, 10, 377
- Collins A, 1997, J Am Soc Nephrol, 8, 190A
Cited by
Sorted by citations
Items 501–600 of 1,000
Mechanisms of Disease: erythropoietin—an old hormone with a new mission?
Fliser, D., Bahlmann, F. H., deGroot, K., & Haller, H. G. (2006) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0609 · Cited by 37
Epidemiology of anemia associated with chronic renal insufficiency
Hsu, C. (2002) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200205000-00011 · Cited by 37
Conlon, P. J., Kovalik, E. C., Schumm, D., Minda, S. A., & Schwab, S. J. (2000) · Renal Failure · doi:10.1081/jdi-100100885 · Cited by 37
Self-citationChronic kidney disease, heart failure and anemia
Virani, S., Khosla, A., & Levin, A. (2008) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(08)71026-2 · Cited by 36
Predialysis versus postdialysis hematocrit evaluation during erythropoietin therapy
Movilli, E., Pertica, N., Camerini, C., Cancarini, G. C., Brunori, G., Scolari, F., & Maiorca, R. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.32007 · Cited by 36
Hemodialysis in children with end-stage renal disease
Müller, D. N., & Goldstein, S. L. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.124 · Cited by 36
Schmidt, R. J., & Dalton, C. (2007) · Osteopathic Medicine and Primary Care · doi:10.1186/1750-4732-1-14 · Cited by 36
ZHANG, X., Dong, S., Qin, Y., & Bian, X. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3155 · Cited by 36
RetractedContinuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease
Saglimbene, V. M., Palmer, S. C., Ruospo, M., Natale, P., Craig, J. C., & Strippoli, G. F. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009904.pub2 · Cited by 36
Hemoglobin is inversely related to flow-mediated dilatation in chronic kidney disease
Yılmaz, M. İ., Sönmez, A., Sağlam, M., Güleç, M., Kılıç, S., Eyileten, T., Çağlar, K., Oğuz, Y., Vural, A., Yenicesu, M., et al. (2009) · Kidney International · doi:10.1038/ki.2009.63 · Cited by 36
Recombinant human erythropoietin in oncology: current status and further developments
Engert, A. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi307 · Cited by 36
Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients
Strippoli, G. F., Tong, A., Palmer, S. C., Elder, G. J., & Craig, J. C. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006254 · Cited by 36
van der Weerd, N. C., den Hoedt, C. H., Blankestijn, P. J., Bots, M. L., van den Dorpel, M. A., Levesque, R. L., Mazairac, A. H. A., Nubé, M. J., Penne, E. L., ter Wee, P. M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094434 · Cited by 35
Fuller, D. S., Bieber, B. A., Pisoni, R. L., Li, Y., Morgenstern, H., Akizawa, T., Jacobson, S. H., Locatelli, F., Port, F. K., & Robinson, B. M. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015060673 · Cited by 35
Rheault, M. N., Molony, J. T., Nevins, T. E., Herzog, C. A., & Chavers, B. M. (2016) · Kidney International · doi:10.1016/j.kint.2016.09.013 · Cited by 35
Ritz, E., Dikow, R., Adamzcak, M., & Zeier, M. G. (2002) · Seminars in Dialysis · doi:10.1046/j.1525-139x.2002.00044.x · Cited by 35
Randomized and Observational Studies in Nephrology: How Strong Is the Evidence?
Greene, T. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.12.001 · Cited by 35
Efficiency of Original versus Generic Intravenous Iron Formulations in Patients on Haemodialysis
Agüera, M. L., Martín‐Malo, A., Alvarez-Lara, M. A., García-Montemayor, V., Canton, P., Soriano, S., & Aljama, P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135967 · Cited by 35
Morbidity and Mortality Reduction Associated with the Use of Erythropoietin
Tsakiris, D. (2000) · The Nephron journals/Nephron journals · doi:10.1159/000045703 · Cited by 35
What is so bad about a hemoglobin level of 12 to 13 g/dL for chronic kidney disease patients anyway?
Besarab, A., Frinak, S., & Yee, J. (2009) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2008.12.007 · Cited by 34
Self-citationBonato, F. O. B., Lemos, M. M., Cassiolato, J. L., & Canziani, M. E. F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066036 · Cited by 34
Iron Deficiency in CKD Without Concomitant Anemia
Wish, J. B., Anker, S. D., Butler, J., Cases, A., Stack, A. G., & Macdougall, I. C. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.07.032 · Cited by 34
Cardiovascular Disease in Patients With Chronic Kidney Disease
Jaradat, M. I., & Molitoris, B. A. (2002) · Seminars in Nephrology · doi:10.1053/snep.2002.35964 · Cited by 34
Chronic kidney disease and cardiovascular risk
Yerram, P., Karuparthi, P. R., Hesemann, L. E., Horst, J. A., & Whaley‐Connell, A. T. (2007) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2007.01.010 · Cited by 34
Posttransplant anemia: the role of sirolimus
Fishbane, S., Cohen, D. J., Coyne, D. W., Djamali, A., Singh, A. K., & Wish, J. B. (2009) · Kidney International · doi:10.1038/ki.2009.231 · Cited by 34
Wish, J. B., & Coyne, D. W. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.11.1371 · Cited by 34
Survival in end stage renal disease: calcium carbonate vs. sevelamer
Borzecki, A. M., Lee, A. F., Wang, S. W., Brenner, L., & Kazis, L. E. (2007) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2007.00871.x · Cited by 34
Lau, J. H., Gangji, A. S., Rabbat, C. G., & Brimble, K. S. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq330 · Cited by 34
Pollak, V. E., Lorch, J. A., Shukla, R., & Satwah, S. (2009) · BMC Nephrology · doi:10.1186/1471-2369-10-6 · Cited by 34
A model of erythropoiesis in adults with sufficient iron availability
Fuertinger, D. H., Kappel, F., Thijssen, S., Levin, N. W., & Kotanko, P. (2012) · Journal of Mathematical Biology · doi:10.1007/s00285-012-0530-0 · Cited by 34
Iaina, A., Silverberg, D. S., & Wexler, D. (2005) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0094 · Cited by 34
Cardiovascular Risk in Patients with Early Renal Insufficiency
Mann, J. F. E., Gerstein, H. C., Pogue, J., Lonn, E., & Yusuf, S. (2002) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200202030-00003 · Cited by 34
Suttorp, M., Hoekstra, T., Rotmans, J. I., Ott, I., Mittelman, M., Krediet, R. T., & Dekker, F. W. (2013) · BMC Nephrology · doi:10.1186/1471-2369-14-200 · Cited by 33
Management of anemia with erythropoietic-stimulating agents in children with chronic kidney disease
Warady, B. A., & Silverstein, D. M. (2013) · Pediatric Nephrology · doi:10.1007/s00467-013-2557-x · Cited by 33
Investigational therapies for renal disease-induced anemia
Schmid, H., & JELKMANN, W. E. B. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1182981 · Cited by 33
Guedes, M. H., Guetter, C. R., Erbano, L. H. O., Palone, A. G., Zee, J., Robinson, B. M., Pisoni, R. L., de Moraes, T. P., Pecoits‐Filho, R., & Baena, C. P. (2020) · BMC Nephrology · doi:10.1186/s12882-020-01912-8 · Cited by 33
Iron therapy in chronic kidney disease: Recent changes, benefits and risks
Ribeiro, S., Belo, L., Reis, F., & Santos‐Silva, A. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.07.006 · Cited by 33
Jun, M., Lv, J., Perkovic, V., & Jardine, M. (2011) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622311401775 · Cited by 33
Anemia management in chronic kidney disease
Fishbane, S. N., & Nissenson, A. R. (2010) · Kidney International · doi:10.1038/ki.2010.188 · Cited by 33
Self-citationInrig, J. K., Bryskin, S. K., Patel, U. D., Arcasoy, M. O., & Szczech, L. A. M. (2011) · BMC Nephrology · doi:10.1186/1471-2369-12-67 · Cited by 33
Risk factors for non-fatal myocardial infarction and cardiac death in incident dialysis patients
Trivedi, H., Xiang, Q., & Klein, J. P. (2008) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn426 · Cited by 33
Clinical use of erythropoietin in chronic kidney disease: outcomes and future prospects.
Provatopoulou, S., & Ziroyiannis, P. (2011) · Europe PMC (PubMed Central) · Cited by 33
Pérez‐García, R., Varas, J., Cives, A., Martín‐Malo, A., Aljama, P., Ramos, R., Pascual, J., Stuard, S., Canaud, B., Merello, J. I., et al. (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfx269 · Cited by 33
2008 JSDT “Guideline for Renal Anemia in Chronic Kidney Disease”
(2008) · Nihon Toseki Igakkai Zasshi · doi:10.4009/jsdt.41.661 · Cited by 33
Aspects of Cardiovascular Burden in Pre-Dialysis Patients
Drüeke, T. B. (2000) · The Nephron journals/Nephron journals · doi:10.1159/000045704 · Cited by 33
Sugimori, H., Tomoda, F., Koike, T., Kurosaki, H., Masutani, T., Ohara, M., Kagitani, S., & Inoue, H. (2012) · Hypertension Research · doi:10.1038/hr.2012.172 · Cited by 32
Bradbury, B. D., Brookhart, M. A., Winkelmayer, W. C., Critchlow, C. W., Kilpatrick, R. D., Joffe, M. M., Feldman, H. I., Acquavella, J., Wang, O., & Rothman, K. J. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2009.05.010 · Cited by 32
Bundled Payment for ESRD — Including ESAs in Medicare's Dialysis Package
Iglehart, J. K. (2011) · New England Journal of Medicine · doi:10.1056/nejmp1014187 · Cited by 32
Briet, M. B., Barhoumi, T., Mian, M. O. R., Sierra, C., Boutouyrie, P., Davidman, M., Bercovitch, D. D., Nessim, S. J., Frisch, G., Paradis, P., et al. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000128 · Cited by 32
Fort, J., Cuevas, X. D. L., López, F. J. G., Pérez‐García, R., Llados, F., Lozano, J., Martín‐Malo, A., & on behalf of all investigators from the ANSWER study (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq073 · Cited by 32
Modulation of stroke risk in chronic kidney disease
Arnold, J. J., Sims, D., & Ferro, C. J. (2015) · Clinical Kidney Journal · doi:10.1093/ckj/sfv136 · Cited by 32
Shukla, A. M., Bose, C., Karaduta, O. K., Apostolov, E. O., Kaushal, G. P., Fahmi, T., Segal, M. S., & Shah, S. V. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139226 · Cited by 32
Managing anemia in dialysis patients: hemoglobin cycling and overshoot
Singh, A. K., Milford, E. L., Fishbane, S. N., & Keithi-Reddy, S. R. (2008) · Kidney International · doi:10.1038/ki.2008.59 · Cited by 32
Potential risk for infection and atherosclerosis due to iron therapy
Sengoelge, G., Sunder–Plassmann, G., & Hörl, W. H. (2005) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2004.09.018 · Cited by 32
HEMATOLOGY: ISSUES IN THE DIALYSIS PATIENT: Nonhematologic Complications of Erythropoietin Therapy
Zhu, X., & Perazella, M. A. (2006) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2006.00173.x · Cited by 32
Collins, A. J., Ebben, J. P., & Gilbertson, D. T. (2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.09.020 · Cited by 32
Medical options to fight mortality in end-stage renal disease: a review of the literature
Kramann, R., Floege, J., Ketteler, M., Marx, N., & Brandenburg, V. M. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs400 · Cited by 31
Treatment of renal anemia: Erythropoiesis stimulating agents and beyond
Biggar, P. H., & Kim, G. (2017) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.2017.36.3.209 · Cited by 31
High sensitivity Troponin-I levels in asymptomatic hemodialysis patients
Tarapan, T., Musikatavorn, K., Phairatwet, P., Takkavatakarn, K., Susantitaphong, P., Eiam‐Ong, S., & Tiranathanagul, K. (2019) · Renal Failure · doi:10.1080/0886022x.2019.1603110 · Cited by 31
Provenzano, R., Tumlin, J. A., Zabaneh, R. I., Chou, J., Hemmerich, S., Neff, T. B., & Yu, K. H. P. (2020) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1648 · Cited by 31
Eckardt, K., Agarwal, R., Farag, Y. M. K., Jardine, A. G., Khawaja, Z., Koury, M. J., Luo, W. F., Matsushita, K., McCullough, P. A., Parfrey, P. S., et al. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa204 · Cited by 31
Fisiopatología del metabolismo del hierro: implicaciones diagnósticas y terapéuticas
Gómez, M. M., Garríguez, A. C., García‐Erce, J. A., & Ramirez, G. (2005) · Nefrología · Cited by 31
Kao, D. P., Kreso, E., Fonarow, G. C., & Krantz, M. J. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.08.046 · Cited by 31
Chan, C. T., Covic, A. C., Craig, J. C., Davenport, A., Kasiske, B. L., Kuhlmann, M. K., Levin, N. W., Li, P. K., Locatelli, F., Rocco, M. V., et al. (2013) · Kidney International · doi:10.1038/ki.2012.450 · Cited by 31
Risk factors of vascular access failure in patients on hemodialysis.
Gheith, O. A. A., & Kamal, M. M. (2008) · Iranian Journal of Kidney Diseases · Cited by 31
Intra- and post-dialytic changes of haemoglobin concentrations in non-anaemic haemodialysis patients
Minutolo, R., Nicola, L. D., Bellizzi, V., Iodice, C., Rubino, R., Aucella, F., Stallone, C., Nappi, F., Avella, F., E, M., et al. (2003) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg387 · Cited by 31
Barbieri, C., Bolzoni, E., Mari, F., Cattinelli, I., Bellocchio, F., Martín‐Guerrero, J. D., Amato, C., Stopper, A., Gatti, E., Macdougall, I. C., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0148938 · Cited by 31
Duce, L., Cooter, M. L., McCartney, S. L., Lombard, F. W., & Guinn, N. R. (2017) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000002418 · Cited by 31
Anemia and cardiovascular disease in diabetic nephropathy
McFarlane, S. I., Salifu, M. O., Makaryus, J. N., & Sowers, J. R. (2006) · Current Diabetes Reports · doi:10.1007/s11892-006-0037-4 · Cited by 31
Management of Neurogenic Orthostatic Hypotension in Patients with Autonomic Failure
Schroeder, C., Jordan, J., & Kaufmann, H. (2013) · Drugs · doi:10.1007/s40265-013-0097-0 · Cited by 30
Anemia and Iron Deficiency in Heart Failure
Arora, N. P., & Ghali, J. K. (2014) · Heart Failure Clinics · doi:10.1016/j.hfc.2013.11.002 · Cited by 30
HEMATOLOGY: ISSUES IN THE DIALYSIS PATIENT: Intravenous Iron Therapy in End‐Stage Renal Disease
Brewster, U. C. (2006) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2006.00174.x · Cited by 30
Causland, F. R. M., Claggett, B. L., Burdmann, E. A., Chertow, G. M., Cooper, M. E., Eckardt, K., Ivanovich, P. T., Levey, A. S., Lewis, E. F., McGill, J. B., et al. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2018.10.006 · Cited by 30
Chung, S., Song, H. C., Shin, S. J., Ihm, S., Park, C. S., Kim, H.-Y., Yang, C. W., Kim, Y., Choi, E. J., & Kim, Y. K. (2011) · Hemodialysis International · doi:10.1111/j.1542-4758.2011.00644.x · Cited by 30
Is Lipid Control Necessary in Hemodialysis Patients?
Cheung, A. K. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04780709 · Cited by 30
Erythropoiesis-Stimulating Agents in Renal Medicine
Locatelli, F., & Vecchio, L. D. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-s3-19 · Cited by 30
Klapholz, M., Abraham, W. T., Ghali, J. K., Ponikowski, P. P., Anker, S. D., Knüsel, B., Sun, Y. P., Wasserman, S. M., & van Veldhuisen, D. J. (2009) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfp130 · Cited by 30
Inrig, J. K., Sapp, S. K., Barnhart, H. X., Patel, U. D., Reddan, D. N., Singh, A. K., Califf, R. M., & Szczech, L. A. M. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs123 · Cited by 30
Streja, E., Park, J., Chan, T.-Y., Lee, J. S., Soohoo, M., Rhee, C. M., Arah, O. A., & Kalantar‐Zadeh, K. (2016) · International Journal of Nephrology · doi:10.1155/2016/6087134 · Cited by 30
Darbepoetin Alfa in Patients with Advanced CKD without Diabetes: Randomized, Controlled Trial
Hayashi, T., Maruyama, S., Nangaku, M., Narita, I., Hirakata, H., Tanabe, K., Morita, S., Tsubakihara, Y., Imai, E., Akizawa, T., et al. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.08900719 · Cited by 30
O’Meara, E., Murphy, C., & McMurray, J. J. V. (2004) · Current Heart Failure Reports · doi:10.1007/s11897-004-0006-7 · Cited by 30
Hörl, W. H., & Ertl, G. (2005) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2005.01526.x · Cited by 30
Cotter, D. J., Thamer, M., Narasimhan, K., Zhang, Y., & Bullock, K. A. (2006) · Health Affairs · doi:10.1377/hlthaff.25.5.1249 · Cited by 30
Adequacy of dialysis revisited
Blake, P. G. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00891.x · Cited by 30
Optimal hematocrit in an artificial microvascular network
Piety, N. Z., Reinhart, W. H., Stutz, J., & Shevkoplyas, S. S. (2017) · Transfusion · doi:10.1111/trf.14213 · Cited by 29
Treatment of Anemia in Kidney Disease: Beyond Erythropoietin
Wish, J. B. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.05.028 · Cited by 29
Barratt, J., Dellanna, F., Portolés, J. M., Choukroun, G. J., Nicola, L. D., Young, J., Dimkovic, N. B., & Reusch, M. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02433-0 · Cited by 29
Krause, K., Jaquet, K., Geidel, S., Schneider, C., Mandel, C., Stoll, H., Hertting, K., Härle, T., & Kück, K. (2006) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2005.10.017 · Cited by 29
Use of agents stimulating erythropoiesis in digestive diseases
López, R. M., Aladrén, B. S., & García, F. G. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.4675 · Cited by 29
Storey, B. C., Staplin, N., Harper, C., Haynes, R., Winearls, C. G., Goldacre, R., Emberson, J., Goldacre, M. J., Baigent, C., Landray, M., et al. (2018) · Kidney International · doi:10.1016/j.kint.2017.11.020 · Cited by 29
Portolés, J. M., de Francisco, Á. L. M., Górriz, J. L., Martínez‐Castelao, A., López–Gómez, J. M., Arias, M., de la Cruz, J. J., Cases, A., Fernández, E., & Aljama, P. (2008) · Kidney International · doi:10.1038/ki.2008.524 · Cited by 29
Haemoglobin concentrations in chronic kidney disease
Steinbrook, R. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69707-9 · Cited by 29
Vaitkus, P. T. (2000) · American Heart Journal · doi:10.1067/mhj.2000.105300 · Cited by 29
Hematopoietic growth factors—use in normal blood and stem cell donors: clinical and ethical issues
McCullough, J., Kahn, J. P., Adamson, J. W., Anderlini, P. N., Benjamin, R. J., Confer, D. L., Eapen, M., Hirsch, B. A., Kuter, D. J., Lazarus, E. F., et al. (2008) · Transfusion · doi:10.1111/j.1537-2995.2008.01788.x · Cited by 28
Locatelli, F., Hannedouche, T. P., Fishbane, S. N., Morgan, Z., Oguey, D., & White, W. B. (2019) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01380219 · Cited by 28
Gilmartin, C. (2007) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070183 · Cited by 28
Ghanta, M., Kozicky, M., & Jim, B. (2014) · Cardiology in Review · doi:10.1097/crd.0000000000000044 · Cited by 28
Yamada, Y., Kobayashi, H., Iwasa, M., Sumi, S., Ushikoshi, H., Aoyama, T., Nishigaki, K., Takemura, G., Fujiwara, T., Fujiwara, H., et al. (2013) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00707.2012 · Cited by 28
A heart price to pay for anaemia
Schunkert, H., & Hense, H. (2001) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/16.3.445 · Cited by 28
Management of the Diabetic Patient with Advanced Chronic Kidney Disease
Alicic, R. Z., & Tuttle, K. R. (2010) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2010.00700.x · Cited by 28
Metadata
- Authors
- Besarab, A., Bolton, W. K., Browne, J. K., Egrie, J. C., Nissenson, A. R., Okamoto, D. M., Schwab, S. J., & Goodkin, D. A.
- Affiliations
- Henry Ford Hospital (US)
- University of Virginia Health System (US)
- Amgen (United States) (US)
- University of California, Los Angeles (US)
- Duke University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1998-08-27
- Volume
- 339
- Issue
- 9
- Pages
- 584-590
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2331665138
- Cited by
- 1,930
- References
- 28
- Citations by year
- 2026: 23 · 2025: 33 · 2024: 36 · 2023: 44 · 2022: 52 · 2021: 82 · 2020: 59 · 2019: 61 · 2018: 59 · 2017: 68 · 2016: 75 · 2015: 56 · 2014: 89 · 2013: 102 · 2012: 99
- FWCI
- 21.09
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Health Sciences › Medicine › Hematology › Blood transfusion and management
- Keywords
- hematocrit, recombinant human erythropoietin, epoetin, hemodialysis, end-stage renal disease, anemia, congestive heart failure, ischemic heart disease, myocardial infarction, mortality, dialysis adequacy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
